SLC5A2 and Hepatic fibrosis: However, there is limited direct evidence to assess the benefits of SGLT-2Is on PH and liver fibrosis in liver cirrhosis, although several clinical trials are ongoing to explore this potential application of SGLT2-Is [30,31].